C82.00 Insurance Policy Changes

ICD-10 C82.00 is officially defined as "Follicular lymphoma grade I, unspecified site." code C82.00 is referenced in 26 tracked payer policy changes from Independence Blue Cross, Excellus BlueCross BlueShield, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code C82.00 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Independence Blue Cross · Effective Nov 2, 2026Medium impact
MA08.139e, Loncastuximab tesirine-lpyl (Zynlonta®)
Independence Blue Cross Medicare Advantage policy MA08.139e adds Waldenstrom macroglobulinemia and lymphoplasmacytic lymphoma as a medically necessary use of Zynlonta (HCPCS J9359) for patients who have had a covalent BTK inhibitor or cannot take one, and adds a list of ICD-10 codes to that coverage. The policy became effective November 2, 2026, so it is already in effect, and it covers Zynlonta only under the Part B medical benefit, not the Part D pharmacy benefit.
Independence Blue Cross · Effective Nov 2, 2026Medium impact
08.00.59e, Loncastuximab tesirine-lpyl (Zynlonta®)
Independence Blue Cross added Waldenstrom macroglobulinemia and lymphoplasmacytic lymphoma as a medically necessary use of Zynlonta (HCPCS J9359) for patients who have had a covalent BTK inhibitor or cannot take one, and it added a long list of ICD-10 codes to that coverage. The policy became effective November 2, 2026, so it is already in effect as of the analysis date, and it applies to IBX commercial plans.
Excellus BlueCross BlueShield · Effective Feb 19, 2026Medium impact
Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) 7.02.02
Excellus medical policy 7.02.02 sets when allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered medically appropriate. It applies when the candidate meets the transplanting institution's selection criteria, the multidisciplinary team evaluates the individual and recommends treatment, and the individual is treated for one of the listed indications. The listed indications include acute and chronic leukemias, non-Hodgkin lymphoma, myelodysplastic diseases at intermediate or high risk, sickle cell anemia under stated criteria, transfusion-dependent thalassemia, bone marrow failure syndromes, severe combined immunodeficiency, hemophagocytic disorders, several storage and leukodystrophy disorders, and certain skeletal and metabolic bone disorders. Allo-HSCT is considered investigational for all other indications. The February 19, 2026 revision simplified the criteria to the indication level, removed the investigational indications list and added HCPCS code S2142.
Aetna · Identified Nov 4, 2026Medium impact
Nivolumab Products (Opdivo, Opdivo Qvantig, and Opdualag) (CPB 0892, reviewed 2026-10-28)
Aetna's clinical policy bulletin CPB 0892, last reviewed 2026-10-28, sets the coverage criteria for nivolumab (Opdivo), nivolumab and hyaluronidase-nvhy (Opdivo Qvantig), and nivolumab and relatlimab-rmbw (Opdualag) for Aetna commercial medical plans, including indication-by-indication initial approval criteria, continuation-of-therapy criteria, and dosing references. Precertification is required for all three products, and the site-of-care utilization management policy applies. The practice's billing team should align charge entry, precertification tracking, and documentation with the indications and continuation limits listed for each product.
Aetna · Identified Oct 24, 2026Medium impact
Epcoritamab-bysp (Epkinly) (CPB 1034, reviewed 2026-10-16)
Aetna's Clinical Policy Bulletin 1034 (reviewed 2026-10-16) establishes coverage criteria for epcoritamab-bysp (Epkinly), a bispecific antibody for treating relapsed or refractory B-cell lymphomas. The policy requires precertification for all Aetna participating providers and members, specifies approved treatment combinations and dosing schedules, and limits certain regimens to a maximum of 12 cycles. All other indications remain experimental/investigational.
Aetna · Identified Oct 18, 2026Medium impact
Ibritumomab Tiuxetan (Zevalin) (CPB 0659, reviewed 2026-10-15)
Aetna's Clinical Policy Bulletin 0659 covers ibritumomab tiuxetan (Zevalin) for commercial medical plans. Aetna considers it medically necessary for relapsed or refractory, low-grade or follicular B-cell non-Hodgkin lymphoma, and for previously untreated follicular non-Hodgkin lymphoma in members who have achieved a partial or complete response to first-line chemotherapy. Aetna considers all other indications experimental, investigational or unproven, and considers a repeat course of treatment not medically necessary.
Aetna · Identified Oct 5, 2026Medium impact
Tisagenlecleucel (Kymriah) (CPB 0920, reviewed 2026-09-11)
Aetna covers tisagenlecleucel (Kymriah) for commercial medical plans. Precertification of tisagenlecleucel is required of all Aetna participating providers and members in applicable plan designs. Covered indications are relapsed or refractory B-cell precursor acute lymphoblastic leukemia in members less than 26 years of age, relapsed or refractory B-cell lymphomas in members 18 years of age or older, relapsed or refractory ALK-positive large B-cell lymphoma if CD19-positive in members 18 years of age or older, and histologic (Richter) transformation to DLBCL in members 18 years of age or older when the stated criteria are met. Aetna considers tisagenlecleucel experimental, investigational or unproven for adults 26 years of age or older with acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, Hodgkin lymphoma, plasma cell disorders, primary central nervous system lymphoma, solid tumors and T-cell leukemia/lymphoma, and it considers repeat administration experimental and investigational.
Aetna · Identified Oct 3, 2026Medium impact
Lisocabtagene Maraleucel (Breyanzi) (CPB 0986, reviewed 2026-09-14)
Aetna's Clinical Policy Bulletin 0986 covers one dose of lisocabtagene maraleucel (Breyanzi) for commercial members 18 or older with specified B-cell lymphomas and chronic lymphocytic leukemia or small lymphocytic lymphoma, each under listed prior-treatment criteria, and for relapsed or refractory pediatric primary mediastinal large B-cell lymphoma after at least two chemoimmunotherapy regimens. Members with primary central nervous system lymphoma, a previous CD19-directed CAR T-cell therapy, an ECOG performance status of 3 or higher, or several listed active or unstable conditions are not eligible. Repeat administration and use for solid tumors are considered experimental, investigational, or unproven.
Aetna · Identified Sep 30, 2026Medium impact
Polatuzumab Vedotin-piiq (Polivy) (CPB 0955, reviewed 2026-09-17)
Aetna's criteria for polatuzumab vedotin-piiq (Polivy) apply to commercial medical plans, and Medicare criteria are in a separate Part B document. Precertification is required for all Aetna participating providers and members in applicable plan designs. Aetna considers Polivy medically necessary for up to 6 cycles for HIV-related B-cell lymphomas, diffuse large B-cell lymphoma, high-grade B-cell lymphomas, histologic transformation of indolent lymphomas, B-cell post-transplant lymphoproliferative disorders, mantle cell lymphoma and Burkitt lymphoma when the listed criteria are met. Continuation is considered medically necessary for up to 6 months (maximum of 6 cycles total) when there is no unacceptable toxicity or disease progression, and all other indications are considered experimental, investigational, or unproven.
Aetna · Identified Sep 29, 2026Medium impact
Brentuximab Vedotin (Adcetris) (CPB 0823, reviewed 2026-09-24)
Aetna considers brentuximab vedotin (Adcetris) medically necessary for commercial medical plans when the request meets one of the listed uses. Listed uses include classic Hodgkin lymphoma as a single agent or in named combinations, relapsed or refractory DLBCL, HGBL and histologic transformation of indolent lymphoma, pediatric primary mediastinal large B-cell lymphoma with nivolumab or pembrolizumab, several CD30-positive T-cell lymphomas and primary cutaneous lymphomas. Reauthorization is considered medically necessary for a listed indication when there is no evidence of unacceptable toxicity or disease progression, and all other indications are considered experimental, investigational, or unproven.
Aetna · Identified Sep 29, 2026Medium impact
Belinostat (Beleodaq) (CPB 0887, reviewed 2026-09-10)
Aetna considers belinostat (Beleodaq) medically necessary for commercial medical plans as a single agent for relapsed or refractory peripheral T-cell lymphoma or for palliative intent, for hepatosplenic T-cell lymphoma after two or more previous lines of chemotherapy, and for relapsed or refractory extranodal NK/T-cell lymphoma with an inadequate response or contraindication to asparaginase-based therapy. It is also considered medically necessary for subsequent therapy in adult T-cell leukemia/lymphoma and breast implant-associated anaplastic large cell lymphoma. Reauthorization is considered medically necessary for a listed indication when there is no evidence of unacceptable toxicity or disease progression on the current regimen, and all other indications, including concomitant use with Folotyn, Istodax, Ninlaro or Zolinza, are considered experimental, investigational, or unproven.
Aetna · Identified Aug 18, 2026Medium impact
Tisagenlecleucel (Kymriah) (CPB 0920, reviewed 2026-02-24)
Aetna Clinical Policy Bulletin 0920 sets the commercial medical coverage criteria for tisagenlecleucel (Kymriah), a CD19-directed autologous CAR T-cell therapy. Aetna considers it medically necessary for relapsed or refractory B-cell precursor acute lymphoblastic leukemia in members under 26 years of age, for specified relapsed or refractory adult B-cell lymphomas (including DLBCL and follicular lymphoma) under stated criteria, for ALK-positive large B-cell lymphoma if CD19-positive, and for histologic (Richter) transformation to DLBCL under stated criteria. Aetna considers all other indications experimental, investigational, or unproven, including adult ALL, AML, CLL, Hodgkin lymphoma, plasma cell disorders, and repeat administration of the therapy.
Aetna · Identified Aug 17, 2026Medium impact
Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma (CPB 0494, reviewed 2026-08-03)
Aetna Clinical Policy Bulletin 0494 covers hematopoietic cell transplantation for non-Hodgkin's lymphoma (NHL). Aetna considers autologous transplant medically necessary for relapsed or primary refractory NHL when the transplanting institution's protocol criteria are met, or, without a protocol, when the person has relapsed or refractory NHL with evidence of chemotherapy-responsive disease. Aetna considers allogeneic transplant medically necessary for relapsed NHL (including relapse after autologous transplant) or primary refractory NHL when a suitable HLA-matched or haploidentical donor or matched cord blood is available and there is no serious organ dysfunction, and considers tandem autologous and autologous-allogeneic transplants experimental, investigational, or unproven for NHL.
Aetna · Identified Aug 17, 2026Medium impact
Tafasitamab-cxix (Monjuvi) (CPB 0979, reviewed 2025-11-04)
Aetna considers tafasitamab-cxix (Monjuvi) medically necessary for commercial medical plans for relapsed or refractory follicular lymphoma when used with lenalidomide and rituximab for up to a maximum of 12 cycles. For other B-cell lymphomas, it is medically necessary in combination with lenalidomide for up to 12 cycles when the member has HIV-related B-cell lymphoma, histologic transformation of indolent lymphoma to DLBCL without eligibility for an autologous stem cell transplant, monomorphic post-transplant lymphoproliferative disorder (B-cell type), DLBCL, or high-grade B-cell lymphoma. Aetna considers all other indications experimental, investigational, or unproven.
Aetna · Identified Aug 16, 2026Medium impact
Mosunetuzumab-axgb (Lunsumio and Lunsumio Velo) (CPB 1025, reviewed 2026-04-24)
Aetna considers mosunetuzumab-axgb (Lunsumio or Lunsumio Velo) medically necessary for follicular lymphoma when the disease had a partial response or no response to treatment or is relapsed or progressive, and the member has tried at least 2 prior lines of systemic therapy. It is also medically necessary for subsequent treatment of diffuse large B-cell lymphoma, high-grade B-cell lymphoma, HIV-related B-cell lymphomas and monomorphic post-transplant lymphoproliferative disorders (B-cell type) when the disease is relapsed or refractory and the drug will be used with polatuzumab vedotin (Lunsumio IV only). Continuation is medically necessary for up to 17 cycles total when there is no evidence of unacceptable toxicity or disease progression.
Aetna · Identified Aug 16, 2026Medium impact
Romidepsin (CPB 0865, reviewed 2026-04-17)
Aetna's Clinical Policy Bulletin 0865 covers romidepsin (Istodax or generic romidepsin) for commercial medical plans when it treats cutaneous T-cell lymphoma, including mycosis fungoides, Sézary syndrome, primary cutaneous anaplastic large cell lymphoma and subcutaneous panniculitis-like T-cell lymphoma, or peripheral T-cell lymphoma. Continuation of therapy is considered medically necessary when there is no evidence of unacceptable toxicity or disease progression on the current regimen. All other indications, including acute myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma and breast cancer, are considered experimental, investigational, or unproven.
Aetna · Identified Aug 16, 2026Medium impact
Rituximab (CPB 0314, reviewed 2026-01-08)
Aetna Clinical Policy Bulletin 0314 sets the criteria for rituximab products (Rituxan, Truxima, Riabni and Ruxience) and rituximab and hyaluronidase (Rituxan Hycela) for commercial medical plans. For Medicare criteria, the policy refers to the Medicare Part B Criteria. Precertification is required of all Aetna participating providers and members in applicable plan designs. The policy lists initial approval criteria by indication, continuation criteria for members who are experiencing benefit, and the prescriber specialties that must prescribe the medication or be consulted. Aetna considers all other hematologic and oncologic indications, and all other indications not listed, experimental, investigational, or unproven.
Aetna · Identified Aug 16, 2026Medium impact
Lisocabtagene Maraleucel (Breyanzi) (CPB 0986, reviewed 2026-03-11)
Aetna Clinical Policy Bulletin 0986 covers lisocabtagene maraleucel (Breyanzi) for commercial medical plans, and Medicare criteria are in a separate document. Aetna considers Breyanzi medically necessary as one dose for adult B-cell lymphomas after at least two lines of systemic therapy, or after first-line chemoimmunotherapy with relapsed or refractory disease in specified subtypes. It is also considered medically necessary for relapsed or refractory mantle cell lymphoma after a covalent Bruton tyrosine kinase inhibitor, relapsed or refractory ALK-positive large B-cell lymphoma if CD19-positive, relapsed or refractory CLL or SLL after a covalent Bruton tyrosine kinase inhibitor and BCL-2 inhibitor regimens, Richter transformation to DLBCL, and relapsed or refractory pediatric primary mediastinal large B-cell lymphoma under age 18. Members with primary central nervous system lymphoma, a previous treatment with Breyanzi or another CD19-directed CAR T-cell therapy, an ECOG performance status of 3 or greater, inadequate and unstable kidney, liver, pulmonary or cardiac function, active hepatitis B or C or other uncontrolled infection, active graft versus host disease, or an active inflammatory disorder are not eligible. Repeat administration and use for solid tumors are considered experimental, investigational, or unproven.
Aetna · Identified Aug 15, 2026Medium impact
Ibritumomab Tiuxetan (Zevalin) (CPB 0659, reviewed 2025-11-26)
Aetna considers ibritumomab tiuxetan (Zevalin) medically necessary for relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL), and for previously untreated follicular NHL in members who have achieved a partial or complete response to first-line chemotherapy. Aetna considers a repeat course of treatment not medically necessary and all other indications experimental, investigational, or unproven. This policy applies to commercial medical plans, and Medicare criteria are in a separate Medicare Part B Criteria document.
Aetna · Identified Aug 13, 2026Medium impact
Polatuzumab Vedotin-piiq (Polivy) (CPB 0955, reviewed 2025-03-13)
Aetna's clinical policy covers polatuzumab vedotin-piiq (Polivy) for commercial medical plans when the criteria for initial approval are met. Those criteria cover HIV-related B-cell lymphomas, diffuse large B-cell lymphoma, high-grade B-cell lymphomas, histologic transformation of indolent lymphomas, B-cell post-transplant lymphoproliferative disorders, mantle cell lymphoma and Burkitt lymphoma, with treatment approved for up to 6 cycles. Aetna considers Polivy experimental, investigational or unproven for all other indications.
Aetna · Identified Aug 13, 2026Medium impact
Plerixafor (CPB 0779, reviewed 2026-02-13)
Aetna's policy covers plerixafor (Mozobil or generic plerixafor) for hematopoietic stem cell mobilization when it is given after a granulocyte-colony stimulating factor such as filgrastim, after chemo-mobilization, or as part of a gene therapy protocol, and when it is not used beyond 4 consecutive days or after stem cell harvest or apheresis is complete. Continuation of therapy is considered medically necessary for members who meet the initial selection criteria. Aetna considers plerixafor experimental, investigational or unproven for all other indications, including the conditions listed in the policy such as acute leukemias, sickle cell disease, WHIM syndrome and neutropenia treatment.
Aetna · Identified Aug 13, 2026Medium impact
Elotuzumab (Empliciti) (CPB 0899, reviewed 2026-03-02)
Aetna Clinical Policy Bulletin 0899 covers elotuzumab (Empliciti) for commercial medical plans and requires precertification for all Aetna participating providers and members in applicable plan designs. Aetna considers elotuzumab medically necessary for previously treated multiple myeloma when it is used with lenalidomide and dexamethasone, with bortezomib and dexamethasone, or with pomalidomide and dexamethasone in members who have received at least two prior therapies, including an immunomodulatory agent and a proteasome inhibitor. The same combinations are considered medically necessary for POEMS syndrome, plasma cell-related monoclonal immunoglobulin deposition disease, and plasma cell-related monoclonal gammopathy of renal significance, and all other indications, including newly diagnosed multiple myeloma and smoldering multiple myeloma, are considered experimental, investigational, or unproven.
Aetna · Identified Aug 12, 2026Medium impact
Bortezomib Products (CPB 0675, reviewed 2026-02-17)
Aetna Clinical Policy Bulletin 0675, last reviewed 02/17/2026, sets commercial medical coverage criteria for bortezomib (Velcade, Boruzu, or generic bortezomib). Aetna considers bortezomib medically necessary for acute lymphoblastic leukemia, adult T-cell leukemia/lymphoma as a single agent for subsequent therapy, Kaposi sarcoma as subsequent therapy, antibody mediated rejection of solid organ, relapsed or refractory follicular lymphoma, relapsed or refractory pediatric classic Hodgkin lymphoma, mantle cell lymphoma, multicentric Castleman disease as subsequent therapy, multiple myeloma, POEMS syndrome, plasma cell-related MIDD and MGRS, systemic light chain amyloidosis, and Waldenström macroglobulinemia/lymphoplasmacytic lymphoma, and considers all other indications experimental, investigational, or unproven, including acute myeloid leukemia, glioblastoma multiforme, and smoldering (asymptomatic) myeloma. Approvals may be subject to dosing limits, and for all indications dosing does not exceed 1.6 mg/m2 per dose or require more than 7 doses per 30-day period.
Aetna · Identified Aug 12, 2026Medium impact
Brentuximab Vedotin (Adcetris) (CPB 0823, reviewed 2026-02-24)
Aetna Clinical Policy Bulletin 0823 covers brentuximab vedotin (Adcetris) for commercial medical plans. For Medicare criteria, see Medicare Part B Criteria. Aetna considers the drug medically necessary for classical Hodgkin lymphoma, CD30-positive B-cell lymphomas, primary cutaneous lymphomas and listed CD30-positive T-cell lymphomas when the stated criteria are met, and considers all other indications experimental, investigational or unproven, including acute myeloid leukemia, mesothelioma, multiple myeloma, renal cell cancer and small cell lung cancer.
Aetna · Identified Aug 12, 2026Medium impact
Belinostat (Beleodaq) (CPB 0887, reviewed 2025-12-09)
Aetna considers belinostat (Beleodaq) medically necessary for commercial plans as a single agent in these cases: peripheral T-cell lymphoma that is relapsed or refractory or used for palliative intent, hepatosplenic T-cell lymphoma after two or more previous lines of chemotherapy, relapsed or refractory extranodal NK/T-cell lymphoma with an inadequate response or contraindication to asparaginase-based therapy, and adult T-cell leukemia/lymphoma or breast implant-associated anaplastic large cell lymphoma used for subsequent therapy. Aetna considers belinostat experimental, investigational, or unproven for all other indications, including B-cell lymphomas, Hodgkin lymphoma, and multiple myeloma, and for concomitant use with Folotyn (pralatrexate), Istodax (romidepsin), Ninlaro (ixazomib), or Zolinza (vorinostat). Continuation of belinostat is medically necessary for a listed indication when there is no evidence of unacceptable toxicity or disease progression on the current regimen.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Radioimmunotherapy in the Treatment of Non-Hodgkin Lymphoma
This policy was last reviewed 06/24/2024 with no changes. A single course of ibritumomab tiuxetan (Zevalin) may be considered medically necessary for the treatment of relapsed or refractory CD20-positive, low-grade or follicular, B-cell non-Hodgkin lymphoma. Its use for consolidation after chemotherapy in CD20-positive follicular non-Hodgkin lymphoma with a partial or complete response may be considered medically necessary, and its use for initial treatment of follicular lymphoma may be considered medically necessary in patients unable to tolerate standard chemotherapy, such as elderly or frail patients. Consolidation of a first remission after chemotherapy for de novo aggressive B-cell NHL and use as part of a preparatory regimen before autologous or allogeneic hematopoietic cell transplantation are investigational.

Watch C82.00

Get one email when a payer policy names C82.00, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code C82.00?

There are 26 tracked policy changes affecting code C82.00, including updates from Independence Blue Cross, Excellus BlueCross BlueShield, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code C82.00?

Payers that have issued tracked updates for code C82.00 include: Independence Blue Cross, Excellus BlueCross BlueShield, Aetna, Blue Cross & Blue Shield of Mississippi.

How do I get notified when code C82.00 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code C82.00. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code C82.00?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

MA08.139e, Loncastuximab tesirine-lpyl (Zynlonta®)

08.00.59e, Loncastuximab tesirine-lpyl (Zynlonta®)

Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) 7.02.02

Nivolumab Products (Opdivo, Opdivo Qvantig, and Opdualag) (CPB 0892, reviewed 2026-10-28)

Epcoritamab-bysp (Epkinly) (CPB 1034, reviewed 2026-10-16)

Ibritumomab Tiuxetan (Zevalin) (CPB 0659, reviewed 2026-10-15)

Tisagenlecleucel (Kymriah) (CPB 0920, reviewed 2026-09-11)

Lisocabtagene Maraleucel (Breyanzi) (CPB 0986, reviewed 2026-09-14)

Polatuzumab Vedotin-piiq (Polivy) (CPB 0955, reviewed 2026-09-17)

Brentuximab Vedotin (Adcetris) (CPB 0823, reviewed 2026-09-24)

Belinostat (Beleodaq) (CPB 0887, reviewed 2026-09-10)

Tisagenlecleucel (Kymriah) (CPB 0920, reviewed 2026-02-24)

Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma (CPB 0494, reviewed 2026-08-03)

Tafasitamab-cxix (Monjuvi) (CPB 0979, reviewed 2025-11-04)

Mosunetuzumab-axgb (Lunsumio and Lunsumio Velo) (CPB 1025, reviewed 2026-04-24)

Romidepsin (CPB 0865, reviewed 2026-04-17)

Rituximab (CPB 0314, reviewed 2026-01-08)

Lisocabtagene Maraleucel (Breyanzi) (CPB 0986, reviewed 2026-03-11)

Ibritumomab Tiuxetan (Zevalin) (CPB 0659, reviewed 2025-11-26)

Polatuzumab Vedotin-piiq (Polivy) (CPB 0955, reviewed 2025-03-13)

Plerixafor (CPB 0779, reviewed 2026-02-13)

Elotuzumab (Empliciti) (CPB 0899, reviewed 2026-03-02)

Bortezomib Products (CPB 0675, reviewed 2026-02-17)

Brentuximab Vedotin (Adcetris) (CPB 0823, reviewed 2026-02-24)

Belinostat (Beleodaq) (CPB 0887, reviewed 2025-12-09)

Radioimmunotherapy in the Treatment of Non-Hodgkin Lymphoma

What insurance policy changes affect code C82.00?

Which payers have updated policy for code C82.00?

How do I get notified when code C82.00 policy changes?

Why do payers change policies for code C82.00?